Diagnostic utility of ZnT3, GluA3 and dynamin 1 in CSF of patients with various clinical dementias
| . | Models . | AUC . | Sensitivity (95% CI) . | Specificity (95% CI) . |
|---|---|---|---|---|
| ZnT3 | MCI | 0.78 | 50% (29.1–70.9) | 100% (82.4–100) |
| MCI- nCv | 0.86 | 64% (35.4–84.8) | 100% (82.4–100) | |
| MCI-Cv | 0.67 | 86% (48.7–99.3) | 50% (29.1–70.9) | |
| Alzheimer’s disease | 0.88 | 83% (60.8–94.2) | 89% (67.2–98.1) | |
| Dyn1 | MCI | 0.66 | 72% (49.1–87.5) | 56% (33.7–75.4) |
| MCI-nCv | 0.57 | 36% (15.2–64.6) | 94% (74.2–99.7) | |
| MCI-Cv | 0.8 | 100% (64.6–100) | 56% (33.7–75.4) | |
| Alzheimer’s disease | 0.85 | 67% (43.8–83.7) | 94% (74.2–99.7) | |
| GLuA3 | MCI | 0.82 | 89% (67.2–98.1) | 61% (38.6–79.7) |
| MCI-nCv | 0.75 | 82% (52.3–96.7) | 61% (38.6–79.7) | |
| MCI-Cv | 0.94 | 86% (48.7–99.3) | 100% (82.4–100) | |
| Alzheimer’s disease | 0.98 | 94% (74.3–99.7) | 100% (82.4–100) |
| . | Models . | AUC . | Sensitivity (95% CI) . | Specificity (95% CI) . |
|---|---|---|---|---|
| ZnT3 | MCI | 0.78 | 50% (29.1–70.9) | 100% (82.4–100) |
| MCI- nCv | 0.86 | 64% (35.4–84.8) | 100% (82.4–100) | |
| MCI-Cv | 0.67 | 86% (48.7–99.3) | 50% (29.1–70.9) | |
| Alzheimer’s disease | 0.88 | 83% (60.8–94.2) | 89% (67.2–98.1) | |
| Dyn1 | MCI | 0.66 | 72% (49.1–87.5) | 56% (33.7–75.4) |
| MCI-nCv | 0.57 | 36% (15.2–64.6) | 94% (74.2–99.7) | |
| MCI-Cv | 0.8 | 100% (64.6–100) | 56% (33.7–75.4) | |
| Alzheimer’s disease | 0.85 | 67% (43.8–83.7) | 94% (74.2–99.7) | |
| GLuA3 | MCI | 0.82 | 89% (67.2–98.1) | 61% (38.6–79.7) |
| MCI-nCv | 0.75 | 82% (52.3–96.7) | 61% (38.6–79.7) | |
| MCI-Cv | 0.94 | 86% (48.7–99.3) | 100% (82.4–100) | |
| Alzheimer’s disease | 0.98 | 94% (74.3–99.7) | 100% (82.4–100) |
Results from ROC curve analyses are visualized in panel A-D and summarized with area under curve (AUC), sensitivity and specificity of synaptic proteins expressed as % with 95% confidence intervals (CI) in parenthesis. Models that were significant (P < 0.05) are presented in bold.
MCI, mild cognitive decline; Cv, converters; nCv, non-converters.
Diagnostic utility of ZnT3, GluA3 and dynamin 1 in CSF of patients with various clinical dementias
| . | Models . | AUC . | Sensitivity (95% CI) . | Specificity (95% CI) . |
|---|---|---|---|---|
| ZnT3 | MCI | 0.78 | 50% (29.1–70.9) | 100% (82.4–100) |
| MCI- nCv | 0.86 | 64% (35.4–84.8) | 100% (82.4–100) | |
| MCI-Cv | 0.67 | 86% (48.7–99.3) | 50% (29.1–70.9) | |
| Alzheimer’s disease | 0.88 | 83% (60.8–94.2) | 89% (67.2–98.1) | |
| Dyn1 | MCI | 0.66 | 72% (49.1–87.5) | 56% (33.7–75.4) |
| MCI-nCv | 0.57 | 36% (15.2–64.6) | 94% (74.2–99.7) | |
| MCI-Cv | 0.8 | 100% (64.6–100) | 56% (33.7–75.4) | |
| Alzheimer’s disease | 0.85 | 67% (43.8–83.7) | 94% (74.2–99.7) | |
| GLuA3 | MCI | 0.82 | 89% (67.2–98.1) | 61% (38.6–79.7) |
| MCI-nCv | 0.75 | 82% (52.3–96.7) | 61% (38.6–79.7) | |
| MCI-Cv | 0.94 | 86% (48.7–99.3) | 100% (82.4–100) | |
| Alzheimer’s disease | 0.98 | 94% (74.3–99.7) | 100% (82.4–100) |
| . | Models . | AUC . | Sensitivity (95% CI) . | Specificity (95% CI) . |
|---|---|---|---|---|
| ZnT3 | MCI | 0.78 | 50% (29.1–70.9) | 100% (82.4–100) |
| MCI- nCv | 0.86 | 64% (35.4–84.8) | 100% (82.4–100) | |
| MCI-Cv | 0.67 | 86% (48.7–99.3) | 50% (29.1–70.9) | |
| Alzheimer’s disease | 0.88 | 83% (60.8–94.2) | 89% (67.2–98.1) | |
| Dyn1 | MCI | 0.66 | 72% (49.1–87.5) | 56% (33.7–75.4) |
| MCI-nCv | 0.57 | 36% (15.2–64.6) | 94% (74.2–99.7) | |
| MCI-Cv | 0.8 | 100% (64.6–100) | 56% (33.7–75.4) | |
| Alzheimer’s disease | 0.85 | 67% (43.8–83.7) | 94% (74.2–99.7) | |
| GLuA3 | MCI | 0.82 | 89% (67.2–98.1) | 61% (38.6–79.7) |
| MCI-nCv | 0.75 | 82% (52.3–96.7) | 61% (38.6–79.7) | |
| MCI-Cv | 0.94 | 86% (48.7–99.3) | 100% (82.4–100) | |
| Alzheimer’s disease | 0.98 | 94% (74.3–99.7) | 100% (82.4–100) |
Results from ROC curve analyses are visualized in panel A-D and summarized with area under curve (AUC), sensitivity and specificity of synaptic proteins expressed as % with 95% confidence intervals (CI) in parenthesis. Models that were significant (P < 0.05) are presented in bold.
MCI, mild cognitive decline; Cv, converters; nCv, non-converters.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
